International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025
Oncological impact of pelvic vessels embolization in patients with locally advanced cervical cancer treated with concomitant chemoradiotherapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peralta Jonathan, Caicedo Lina, Rodríguez Juliana, Viveros-Carreño David, Vieira-Serna Santiago, Lemus Marcela Núñez, Almeciga Adriana, Narváez Andrés Erazo, Caicedo-Martínez María, Pareja René
Аннотация
OBJECTIVE: This study aims to address the impact of pelvic vessel embolization on oncological outcomes in patients with locally advanced cervical cancer treated with concomitant chemoradiotherapy.
METHODS: This is a retrospective single-center cohort study including patients with locally advanced cervical cancer (International Federation of Gynecology and Obstetrics 2018 stages IB3-IVA), treated between January, 2010, and December, 2020. The primary outcome was overall survival, and the secondary outcome was disease-free survival. An inverse probability of treatment weighting was applied to balance baseline characteristics between groups and generate comparable cohorts.
RESULTS: A total of 344 patients were included, of whom 8.4% (n = 29) underwent pelvic vessel embolization before the initiation of definitive treatment with concomitant chemoradiotherapy. In the embolized group, most (75.8%, n = 22) were classified as International Federation of Gynecology and Obstetrics 2018 stage III, and 44.8% of them (n = 13) had hemoglobin levels <10 g/dL before starting treatment. Overall survival rates were significantly worse in the embolized group in the analysis after inverse probability of treatment weighting (hazard ratio [HR] 2.60 [1.20-5.64], p < .05), however no statistically significant differences were observed in disease-free survival between embolized and non-embolized patients (HR 2.05 [0.91-4.59], p > .05).
CONCLUSIONS: Patients with cervical cancer who underwent pelvic vessel embolization had worse overall survival in this cohort. Further studies are required to confirm this association.
METHODS: This is a retrospective single-center cohort study including patients with locally advanced cervical cancer (International Federation of Gynecology and Obstetrics 2018 stages IB3-IVA), treated between January, 2010, and December, 2020. The primary outcome was overall survival, and the secondary outcome was disease-free survival. An inverse probability of treatment weighting was applied to balance baseline characteristics between groups and generate comparable cohorts.
RESULTS: A total of 344 patients were included, of whom 8.4% (n = 29) underwent pelvic vessel embolization before the initiation of definitive treatment with concomitant chemoradiotherapy. In the embolized group, most (75.8%, n = 22) were classified as International Federation of Gynecology and Obstetrics 2018 stage III, and 44.8% of them (n = 13) had hemoglobin levels <10 g/dL before starting treatment. Overall survival rates were significantly worse in the embolized group in the analysis after inverse probability of treatment weighting (hazard ratio [HR] 2.60 [1.20-5.64], p < .05), however no statistically significant differences were observed in disease-free survival between embolized and non-embolized patients (HR 2.05 [0.91-4.59], p > .05).
CONCLUSIONS: Patients with cervical cancer who underwent pelvic vessel embolization had worse overall survival in this cohort. Further studies are required to confirm this association.